Advertisement
CLYM vs IMNM
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLYM is a Buy and IMNM is a StrongBuy.
CLYM's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for CLYM turned positive on October 20, 2026. Looking at past instances where CLYM's MACD turned positive, the stock continued to rise in 49 of 56 cases over the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CLYM's RSI Indicator exited the oversold zone, 16 of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on CLYM as a result. In 107 of 127 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
CLYM moved above its 50-day moving average on November 11, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +11.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLYM advanced for three days, in 193 of 239 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLYM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
CLYM broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CLYM entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.467) is normal, around the industry mean (3.498). P/E Ratio (-12.549) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. CLYM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLYM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
IMNM sees its Stochastic Oscillator recovers from oversold territory
On November 11, 2026, the Stochastic Oscillator for IMNM moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 64 instances where the indicator left the oversold zone. In 58 of the 64 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IMNM's RSI Indicator exited the oversold zone, 29 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on November 11, 2026. You may want to consider a long position or call options on IMNM as a result. In 68 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for IMNM just turned positive on October 22, 2026. Looking at past instances where IMNM's MACD turned positive, the stock continued to rise in 33 of 45 cases over the following month. The odds of a continued upward trend are 73%.
Following a +8.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMNM advanced for three days, in 236 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The 50-day moving average for IMNM moved below the 200-day moving average on October 30, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMNM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
IMNM broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IMNM entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. IMNM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.047) is normal, around the industry mean (3.498). P/E Ratio (-7.395) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (625.000) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 95 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMNM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
IMNM | ||
|---|---|---|
OUTLOOK RATING 1..100 | 21 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 70 Overvalued | |
PROFIT vs RISK RATING 1..100 | 95 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 62 | |
P/E GROWTH RATING 1..100 | 25 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| CLYM | IMNM | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 80% | 2 days ago 85% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 84% | 2 days ago 88% |
| MACD ODDS (%) | 2 days ago 88% | 2 days ago 73% |
| TrendWeek ODDS (%) | 2 days ago 83% | 2 days ago 86% |
| TrendMonth ODDS (%) | 2 days ago 85% | 2 days ago 85% |
| Advances ODDS (%) | 2 days ago 81% | 4 days ago 83% |
| Declines ODDS (%) | 8 days ago 89% | 8 days ago 86% |
| BollingerBands ODDS (%) | 2 days ago 89% | 2 days ago 77% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 80% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CLYM’s FA Score shows that 2 FA rating(s) are green while IMNM’s FA Score has 1 green FA rating(s).
- CLYM’s FA Score: 2 green, 3 red.
- IMNM’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CLYM’s TA Score shows that 5 TA indicator(s) are bullish while IMNM’s TA Score has 5 bullish TA indicator(s).
- CLYM’s TA Score: 5 bullish, 4 bearish.
- IMNM’s TA Score: 5 bullish, 4 bearish.
Price Growth
CLYM (@Biotechnology) experienced а +31.30% price change this week, while IMNM (@Biotechnology) price change was -2.31% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
CLYM is expected to report earnings on Mar 08, 2027.
IMNM is expected to report earnings on Mar 25, 2027.
Industries' Descriptions
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CLYM and
Correlation & Price change
A.I.dvisor indicates that over the last year, CLYM has been loosely correlated with KYTX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CLYM jumps, then KYTX could also see price increases.
| Ticker / NAME | Correlation To CLYM | 1D Price Change % | ||
|---|---|---|---|---|
| CLYM | 100% | +4.34% | ||
| KYTX - CLYM | 43% Loosely correlated | +0.79% | ||
| IMNM - CLYM | 42% Loosely correlated | +2.25% | ||
| FDMT - CLYM | 41% Loosely correlated | +4.25% | ||
| IMVT - CLYM | 41% Loosely correlated | +3.72% | ||
| CABA - CLYM | 40% Loosely correlated | N/A | ||
More | ||||